Richard Kornbluth | President & Chief Scientific Officer
Multimeric Biotherapeutics, Inc.

Richard Kornbluth, President & Chief Scientific Officer, Multimeric Biotherapeutics, Inc.

Dr. Richard Kornbluth is an immunologist, physician, and serial entrepreneur. Richard trained at Harvard (A.B.), New York Medical College (M.D.), Columbia University (Ph.D.), and the Scripps Research Institute (postdoc). He was a faculty member at Univ. Calif. San Diego where he worked on HIV vaccines and immunology. He founded Multimeric Biotherapeutics, Inc. to develop the technology he invented for making highly active, soluble TNF SuperFamily ligands (TNFSFs), focusing on CD40L which is a powerful activator of dendritic cells. In collaboration with Geoffrey W. Stone, Ph.D. (his former post-doc), he developed FortiVac™ as a next generation vaccine technology for eliciting very strong CD8+ T cell responses against viruses and cancer.


WVIC/WAC Day 1 - Nov 29 @ 15:20

FortiVac APC-targeted vaccine for powerful CD8+ T cell responses

last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall